1. Home
2. Coding Rules
3. Adult diagnoses (age 15 through 124)

Adult diagnoses (age 15 through 124). — See additional coding rules

• T46.3X5A Adverse effect of coronary vasodilators, initial encounter
• T46.3X5D Adverse effect of coronary vasodilators, subsequent encounter
• T46.3X5S Adverse effect of coronary vasodilators, sequela
• T46.3X6A Underdosing of coronary vasodilators, initial encounter
• T46.3X6D Underdosing of coronary vasodilators, subsequent encounter
• T46.3X6S Underdosing of coronary vasodilators, sequela
• T46.4X5A Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter
• T46.4X5D Adverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter
• T46.4X5S Adverse effect of angiotensin-converting-enzyme inhibitors, sequela
• T46.4X6A Underdosing of angiotensin-converting-enzyme inhibitors, initial encounter
• T46.4X6D Underdosing of angiotensin-converting-enzyme inhibitors, subsequent encounter
• T46.4X6S Underdosing of angiotensin-converting-enzyme inhibitors, sequela
• T46.5X5A Adverse effect of other antihypertensive drugs, initial encounter
• T46.5X5D Adverse effect of other antihypertensive drugs, subsequent encounter
• T46.5X5S Adverse effect of other antihypertensive drugs, sequela
• T46.5X6A Underdosing of other antihypertensive drugs, initial encounter
• T46.5X6D Underdosing of other antihypertensive drugs, subsequent encounter
• T46.5X6S Underdosing of other antihypertensive drugs, sequela
• T46.6X5A Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
• T46.6X5D Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
• T46.6X5S Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
• T46.6X6A Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
• T46.6X6D Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
• T46.6X6S Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, sequela
• T46.7X5A Adverse effect of peripheral vasodilators, initial encounter
• T46.7X5D Adverse effect of peripheral vasodilators, subsequent encounter
• T46.7X5S Adverse effect of peripheral vasodilators, sequela
• T46.7X6A Underdosing of peripheral vasodilators, initial encounter
• T46.7X6D Underdosing of peripheral vasodilators, subsequent encounter
• T46.7X6S Underdosing of peripheral vasodilators, sequela
• T46.8X5A Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter
• T46.8X5D Adverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter
• T46.8X5S Adverse effect of antivaricose drugs, including sclerosing agents, sequela
• T46.8X6A Underdosing of antivaricose drugs, including sclerosing agents, initial encounter
• T46.8X6D Underdosing of antivaricose drugs, including sclerosing agents, subsequent encounter
• T46.8X6S Underdosing of antivaricose drugs, including sclerosing agents, sequela
• T46.905A Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter
• T46.905D Adverse effect of unspecified agents primarily affecting the cardiovascular system, subsequent encounter
• T46.905S Adverse effect of unspecified agents primarily affecting the cardiovascular system, sequela
• T46.906A Underdosing of unspecified agents primarily affecting the cardiovascular system, initial encounter
• T46.906D Underdosing of unspecified agents primarily affecting the cardiovascular system, subsequent encounter
• T46.906S Underdosing of unspecified agents primarily affecting the cardiovascular system, sequela
• T46.995A Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter
• T46.995D Adverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter
• T46.995S Adverse effect of other agents primarily affecting the cardiovascular system, sequela
• T46.996A Underdosing of other agents primarily affecting the cardiovascular system, initial encounter
• T46.996D Underdosing of other agents primarily affecting the cardiovascular system, subsequent encounter
• T46.996S Underdosing of other agents primarily affecting the cardiovascular system, sequela
• T47.0X5A Adverse effect of histamine H2-receptor blockers, initial encounter
• T47.0X5D Adverse effect of histamine H2-receptor blockers, subsequent encounter
• T47.0X5S Adverse effect of histamine H2-receptor blockers, sequela
• T47.0X6A Underdosing of histamine H2-receptor blockers, initial encounter
• T47.0X6D Underdosing of histamine H2-receptor blockers, subsequent encounter
• T47.0X6S Underdosing of histamine H2-receptor blockers, sequela
• T47.1X5A Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter
• T47.1X5D Adverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter
• T47.1X5S Adverse effect of other antacids and anti-gastric-secretion drugs, sequela
• T47.1X6A Underdosing of other antacids and anti-gastric-secretion drugs, initial encounter
• T47.1X6D Underdosing of other antacids and anti-gastric-secretion drugs, subsequent encounter
• T47.1X6S Underdosing of other antacids and anti-gastric-secretion drugs, sequela
• T47.2X5A Adverse effect of stimulant laxatives, initial encounter
• T47.2X5D Adverse effect of stimulant laxatives, subsequent encounter
• T47.2X5S Adverse effect of stimulant laxatives, sequela
• T47.2X6A Underdosing of stimulant laxatives, initial encounter
• T47.2X6D Underdosing of stimulant laxatives, subsequent encounter
• T47.2X6S Underdosing of stimulant laxatives, sequela
• T47.3X5A Adverse effect of saline and osmotic laxatives, initial encounter
• T47.3X5D Adverse effect of saline and osmotic laxatives, subsequent encounter
• T47.3X5S Adverse effect of saline and osmotic laxatives, sequela
• T47.3X6A Underdosing of saline and osmotic laxatives, initial encounter
• T47.3X6D Underdosing of saline and osmotic laxatives, subsequent encounter
• T47.3X6S Underdosing of saline and osmotic laxatives, sequela
• T47.4X5A Adverse effect of other laxatives, initial encounter
• T47.4X5D Adverse effect of other laxatives, subsequent encounter
• T47.4X5S Adverse effect of other laxatives, sequela
• T47.4X6A Underdosing of other laxatives, initial encounter
• T47.4X6D Underdosing of other laxatives, subsequent encounter
• T47.4X6S Underdosing of other laxatives, sequela
• T47.5X5A Adverse effect of digestants, initial encounter
• T47.5X5D Adverse effect of digestants, subsequent encounter
• T47.5X5S Adverse effect of digestants, sequela
• T47.5X6A Underdosing of digestants, initial encounter
• T47.5X6D Underdosing of digestants, subsequent encounter
• T47.5X6S Underdosing of digestants, sequela
• T47.6X5A Adverse effect of antidiarrheal drugs, initial encounter
• T47.6X5D Adverse effect of antidiarrheal drugs, subsequent encounter
• T47.6X5S Adverse effect of antidiarrheal drugs, sequela
• T47.6X6A Underdosing of antidiarrheal drugs, initial encounter
• T47.6X6D Underdosing of antidiarrheal drugs, subsequent encounter
• T47.6X6S Underdosing of antidiarrheal drugs, sequela
• T47.7X5A Adverse effect of emetics, initial encounter
• T47.7X5D Adverse effect of emetics, subsequent encounter
• T47.7X5S Adverse effect of emetics, sequela
• T47.7X6A Underdosing of emetics, initial encounter
• T47.7X6D Underdosing of emetics, subsequent encounter
• T47.7X6S Underdosing of emetics, sequela
• T47.8X5A Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter
• T47.8X5D Adverse effect of other agents primarily affecting gastrointestinal system, subsequent encounter
• T47.8X5S Adverse effect of other agents primarily affecting gastrointestinal system, sequela
• T47.8X6A Underdosing of other agents primarily affecting gastrointestinal system, initial encounter